Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

Neurocrine Biosciences, Inc., San Diego, California

JCP
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
Narrative Review

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
, , , et al

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe